In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation
In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation
复制标题
DOI：
10.1182/blood.v90.11.4297.4297_4297_4306
复制
发表时间：
1997-12-01
期刊：
影响因子：
20.3
通讯作者：
Nadler, LM
中科院分区：
文献类型：
--
作者：
Dorfman, DM;Schultze, JL;Nadler, LM
B7家族共刺激分子在B细胞上的表达决定了其作为抗原呈递细胞（APC）的功能，不表达B7共刺激分子的B细胞诱导T细胞耐受，因此，B7共刺激分子在恶性肿瘤B细胞上的表达可能是其被抗肿瘤特异性T细胞识别的关键。在这里，我们发现，几乎所有的生发中心（GC）来源的B细胞淋巴瘤，包括滤泡性淋巴瘤（FL）和弥漫性大细胞淋巴瘤，但不是套细胞淋巴瘤或小淋巴细胞淋巴瘤（SLL/CLL），表达B7-1（CD 80）和B7-2（CD 86）在其细胞表面原位，虽然在极低的水平，尽管他们表达低水平的B7-1和B7-2，FL细胞不能诱导明显的同种异体T细胞增殖，但是FL上的B7共刺激分子似乎是功能性的，因为它们能够在二次同种异体混合淋巴细胞反应中增加预活化的T细胞的T细胞增殖。此外，低B7表达足以防止在体外诱导同种异体抗原特异性无能。因此，我们推测，虽然B7的低水平表达不足以启动生产性抗淋巴瘤T细胞反应，但可能足以防止体内T细胞耐受。(C)1997年，美国血液学会。
Expression of B7 family costimulatory molecules on B cells defines their capacity to function as antigen presenting cells (APCs), B cells that do not express B7 costimulatory molecules induce T-cell tolerance, Therefore, the expression of B7 costimulatory molecules on malignant B cells might be critical for their recognition by anti-tumor-specific T cells. Here we show that virtually all germinal center (GC)-derived B-cell lymphomas including follicular lymphoma (FL) and diffuse large cell lymphoma, but not mantle cell lymphoma or small lymphocytic lymphomas (SLL/CLL), express B7-1 (CD80) and B7-2 (CD86) on their cell surface in situ, although at extremely low levels, Despite their expression of low levels of B7-1 and B7-2, FL cells could not induce significant allogeneic T-cell proliferation, However, B7 costimulatory molecules on FL appeared to be functional because they were capable of increasing T-cell proliferation of preactivated T cells in a secondary allogeneic mixed lymphocyte response. Moreover, low B7 expression was sufficient to prevent the induction of alloantigen-specific anergy in vitro. Therefore, we postulate that whereas low-level expression of B7 is not sufficient to initiate a productive antilymphoma T-cell response, it might be sufficient to prevent T-cell tolerance in vivo. (C) 1997 by The American Society of Hematology.